Literature DB >> 12829026

Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation.

Dieter Kirchner1, Justus Duyster, Oliver Ottmann, Roland M Schmid, Lothar Bergmann, Gerd Munzert.   

Abstract

Bcr-Abl constitutes a deregulated tyrosine kinase involved in the pathogenesis of chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL). Although activation of the transcription factor NF-kappaB/Rel has been demonstrated, mechanisms of NF-kappaB/Rel activation by Bcr-Abl remain obscure. In this paper we demonstrate activation of NF-kappaB/Rel by Bcr-Abl and for the first time by v-Abl. Furthermore, we investigated mechanisms of NF-kappaB/Rel induction by Bcr-Abl and v-Abl. Both Bcr-Abl and v-Abl induced NF-kappaB/Rel DNA binding in Ba/F3 cells. DNA binding was a result of nuclear translocation of p65/RelA, whereas p65/RelA expression was unaffected. Nuclear translocation of p65/RelA is at least partially due to increased IkappaBalpha degradation, which is independent of IkappaB kinase (IKK) activity. IKK activity is not deregulated by Bcr-Abl and v-Abl. NF-kappaB/Rel transactivation was dependent on abl kinase activity but independent of Grb2 and Grb10 binding tobcr sequences. In addition, NF-kappaB/Rel activation was dependent on Ras activity. Primary CML blasts showed constitutive p65/RelA NF-kappaB/Rel DNA binding activity. Thus NF-kappaB/Rel represents a potential target for molecular therapies in CML.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829026     DOI: 10.1016/s0301-472x(03)00069-9

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  21 in total

1.  Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.

Authors:  Teodora Pene-Dumitrescu; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

Review 2.  Inhibition of Ras-mediated signaling pathways in CML stem cells.

Authors:  Jessika Bertacchini; Neda Ketabchi; Laura Mediani; Silvano Capitani; Sandra Marmiroli; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-10-12       Impact factor: 6.730

3.  Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.

Authors:  Geoffrey A Bartholomeusz; Moshe Talpaz; Vaibhav Kapuria; Ling Yuan Kong; Shimei Wang; Zeev Estrov; Waldemar Priebe; Ji Wu; Nicholas J Donato
Journal:  Blood       Date:  2007-01-03       Impact factor: 22.113

4.  High frequency of MEFV gene mutations in patients with myeloid neoplasm.

Authors:  Cagatay Oktenli; Ozkan Sayan; Serkan Celik; Alev A Erikci; Yusuf Tunca; Hakan M Terekeci; Elcin Erkuvan Umur; Yavuz S Sanisoglu; Deniz Torun; Fatih Tangi; Burak Sahan; Selim Nalbant
Journal:  Int J Hematol       Date:  2010-05-01       Impact factor: 2.490

Review 5.  NF-κB pathways in hematological malignancies.

Authors:  Chiara Gasparini; Claudio Celeghini; Lorenzo Monasta; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2014-01-14       Impact factor: 9.261

6.  CD150(-) Side Population Defines Leukemia Stem Cells in a BALB/c Mouse Model of CML and Is Depleted by Genetic Loss of SIRT1.

Authors:  Zhiqiang Wang; Ching-Cheng Chen; WenYong Chen
Journal:  Stem Cells       Date:  2015-10-15       Impact factor: 6.277

Review 7.  High frequency of inherited variants in the MEFV gene in patients with hematologic neoplasms: a genetic susceptibility?

Authors:  Cagatay Oktenli; Serkan Celik
Journal:  Int J Hematol       Date:  2012-03-28       Impact factor: 2.490

8.  IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.

Authors:  Mo-Ying Hsieh; Richard A Van Etten
Journal:  Blood       Date:  2014-01-24       Impact factor: 22.113

9.  Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.

Authors:  Zhongzheng Lu; Yanli Jin; Chun Chen; Juan Li; Qi Cao; Jingxuan Pan
Journal:  Mol Cancer       Date:  2010-05-19       Impact factor: 27.401

10.  Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo.

Authors:  Yan-lin Wei; Lei Xu; Yun Liang; Xiao-hua Xu; Xiao-ying Zhao
Journal:  Acta Pharmacol Sin       Date:  2009-03-09       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.